---
title: 'Regulatory Daily Summary: What Happened on October 31, 2026'
headline: FDA advisers favor another Sydnexis trial for pediatric myopia drug
description: The panel questioned whether SYD-101’s Phase III results showed a clinically
  meaningful benefit, although the lower dose met prespecified endpoints.
url: https://thebench.bio/news/regulatory/2026-10-31
topic: regulatory
date: '2026-10-31'
covers:
- '2026-10-31'
date_published: '2026-10-31T12:01:00Z'
date_modified: '2026-10-31T12:01:00Z'
tags:
- Regulatory
sources: 1
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on October 31, 2026

**FDA advisers favor another Sydnexis trial for pediatric myopia drug**

The panel questioned whether SYD-101’s Phase III results showed a clinically meaningful benefit, although the lower dose met prespecified endpoints.

## Today in brief

The advisory panel backed further testing of Sydnexis’ low-dose atropine treatment, concluding the evidence had not established meaningful benefit for children with myopia. [1]

## Also published

- [At least 11 PDUFAs on FDA’s November docket](<https://www.biocentury.com/article/661395/at-least-11-pdufas-on-fda-s-november-docket?utm_source=bc_rss&utm_medium=rss>), BioCentury

## Sources

1. [Widespread atropine use fails to sway FDA advisors on Sydnexis data](<https://www.biocentury.com/article/661385/widespread-atropine-use-fails-to-sway-fda-advisors-on-sydnexis-data?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-10-31

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661385/widespread-atropine-use-fails-to-sway-fda-advisors-on-sydnexis-data?utm_source=bc_rss&utm_medium=rss>